دورية أكاديمية
In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.
| العنوان: | In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients. |
|---|---|
| المؤلفون: | Ratjen A; Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada., Yau Y; Division of Microbiology, Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada., Wettlaufer J; Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada., Matukas L; Division of Microbiology, Department of Laboratory Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada., Zlosnik JE; Division of Infectious Diseases, Department of Pediatrics, Centre for Understanding and Preventing Infection in Children, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada., Speert DP; Division of Infectious Diseases, Department of Pediatrics, Centre for Understanding and Preventing Infection in Children, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada., LiPuma JJ; Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA., Tullis E; Division of Respirology and Keenan Research Centre of Li Ka Shing Knowledge Institute, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada., Waters V; Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada valerie.waters@sickkids.ca. |
| المصدر: | Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2015 Jan; Vol. 59 (1), pp. 711-3. Date of Electronic Publication: 2014 Oct 27. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, American Society for Microbiology |
| مواضيع طبية MeSH: | Anti-Bacterial Agents/*therapeutic use , Burkholderia cepacia complex/*drug effects , Cystic Fibrosis/*microbiology , Stenotrophomonas maltophilia/*drug effects , Tobramycin/*therapeutic use, Anti-Bacterial Agents/pharmacology ; Biofilms/drug effects ; Burkholderia Infections/drug therapy ; Burkholderia Infections/etiology ; Burkholderia Infections/microbiology ; Cystic Fibrosis/complications ; Gram-Negative Bacterial Infections/drug therapy ; Gram-Negative Bacterial Infections/etiology ; Gram-Negative Bacterial Infections/microbiology ; Humans ; Microbial Sensitivity Tests ; Tobramycin/pharmacology |
| مستخلص: | Burkholderia cepacia complex and Stenotrophomonas maltophilia infections are associated with poor clinical outcomes in persons with cystic fibrosis (CF). The MIC50 based on planktonic growth and the biofilm concentration at which 50% of the isolates tested are inhibited (BIC50) of tobramycin were measured for 180 B. cepacia complex and 101 S. maltophilia CF isolates and were 100 μg/ml for both species. New inhalation devices that deliver high tobramycin levels to the lung may be able to exceed these MICs. (Copyright © 2015, American Society for Microbiology. All Rights Reserved.) |
| References: | BMC Microbiol. 2009 Sep 17;9:200. (PMID: 19761586) J Pediatr. 1985 Sep;107(3):382-7. (PMID: 4032134) Antimicrob Agents Chemother. 2013 Mar;57(3):1546-8. (PMID: 23295930) J Antimicrob Chemother. 2002 Aug;50(2):265-9. (PMID: 12161410) J Cyst Fibros. 2009 Jul;8(4):291-3. (PMID: 19411195) Antimicrob Agents Chemother. 2011 May;55(5):2256-64. (PMID: 21321142) Am J Respir Crit Care Med. 2011 Mar 1;183(5):635-40. (PMID: 20889901) Cochrane Database Syst Rev. 2012 Oct 17;10:CD009529. (PMID: 23076960) Nat Rev Drug Discov. 2013 Oct;12(10):791-808. (PMID: 24080700) J Cyst Fibros. 2012 Sep;11(5):458-60. (PMID: 22551926) J Clin Microbiol. 1999 Jun;37(6):1771-6. (PMID: 10325322) Microbiology (Reading). 2014 Jul;160(Pt 7):1332-1345. (PMID: 24728272) FEMS Microbiol Lett. 2003 Nov 7;228(1):57-62. (PMID: 14612237) J Cyst Fibros. 2011 Jan;10(1):54-61. (PMID: 21075062) J Cyst Fibros. 2013 Sep;12(5):482-6. (PMID: 23294530) Front Cell Infect Microbiol. 2011 Dec 21;1:18. (PMID: 22919584) Am J Transplant. 2008 May;8(5):1025-30. (PMID: 18318775) Curr Pharm Des. 2012;18(5):696-725. (PMID: 22229574) Chest. 2001 Sep;120(3 Suppl):118S-123S. (PMID: 11555566) Clin Microbiol Rev. 2012 Jan;25(1):2-41. (PMID: 22232370) Am J Epidemiol. 1996 May 15;143(10):1007-17. (PMID: 8629607) J Antimicrob Chemother. 2012 Nov;67(11):2673-81. (PMID: 22843834) |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) VZ8RRZ51VK (Tobramycin) |
| تواريخ الأحداث: | Date Created: 20141029 Date Completed: 20150824 Latest Revision: 20211021 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC4291427 |
| DOI: | 10.1128/AAC.04123-14 |
| PMID: | 25348526 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1098-6596 |
|---|---|
| DOI: | 10.1128/AAC.04123-14 |